New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1Aschenbrenner, Diane S. MS, RNAJN The American Journal of Nursing: December 2013 - Volume 113 - Issue 12 - p 22 doi: 10.1097/01.NAJ.0000438862.37283.a8 Drug Watch Abstract Author Information A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection. Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C. Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com. © 2013 Lippincott Williams & Wilkins. All rights reserved.